Sunday 9 September 2018
Pharma major Wockhardt has expanded into the Middle East by setting up a manufacturing facility for new chemical entities (NCEs) catering to the global markets through the Dubai arm of its subsidiary Wockhardt Bio AG.
The state-of-the-art manufacturing facility for the production and packaging of sterile dry powder injection in Dubai is awaiting US Federal Drug Authority (FDA) approval on the new drug to begin commercial production.
The facility will focus its efforts on creating products to counter antimicrobial resistance (AMR) – the ability of infections to resist antibiotics – also called ‘superbugs’.
“Wockhardt conducted extensive studies for identifying a region in the Middle East to establish a strong manufacturing presence for its advanced patented drugs. Jebel Ali Free Zone was found to be appropriate for the factory premises for manufacturing patented proprietary drugs for global markets,” the company said.
The manufacturing facility is designed to meet standards of various international regulatory agencies and the standards set by the UAE’s Ministry of Health. It is dedicated to launch its novel NCE products’ antibiotics segment to the world from the UAE. The facility is spread over 10,000 square meters and is sufficient for handling warehousing, manufacturing operations, product testing, and product stability.